Chuang Yu-Fan, Wang Peng-Yuan, Kumar Satheesh, Lama Suraj, Lin Fan-Li, Liu Guei-Sheung
Shenzhen Key Laboratory of Biomimetic Materials and Cellular Immunomodulation, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
Front Cell Dev Biol. 2021 Jun 11;9:667879. doi: 10.3389/fcell.2021.667879. eCollection 2021.
Specific changes in the genome have been accomplished by the revolutionary gene-editing tool known as clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) system. The advent of programmable RNA editing CRISPR/Cas nucleases has made this gene-editing tool safer and more precise. Specifically, CasRx, a family member of the Cas13d family, has shown great therapeutic potential. Here, we describe the methods of utilizing this powerful RNA editing platform and determine the RNA editing efficiencies for CasRx with different forms of guide RNAs (also known as gRNA or sgRNA).
一种名为成簇规律间隔短回文重复序列（CRISPR）/CRISPR相关蛋白（Cas）系统的革命性基因编辑工具，已实现了基因组的特定改变。可编程RNA编辑CRISPR/Cas核酸酶的出现，使这种基因编辑工具更安全、更精确。具体而言，Cas13d家族成员CasRx已显示出巨大的治疗潜力。在此，我们描述了利用这一强大RNA编辑平台的方法，并确定了CasRx对不同形式引导RNA（也称为gRNA或sgRNA）的RNA编辑效率。
